Trinity Delta Lighthouse: Futura Medical
Trinity Delta view: The fund raise extends Futura Medical’s cash runway, on current plans, through to end-2020. We suspended our forecasts and valuation when the FM57 study results were announced. As we said at the time, these remarkable results have created understandable uncertainty and until we have greater visibility that is the prudent action to take. There are clear opportunities for DermaSys being approved as a treatment for ED, including the extended patent life and wider market opportunities; however, there are potential unknowns that remain. The planned meeting with the FDA will shed further light on the next steps. We intend to reinstate our forecasts as soon as practicable.Futura Medical is engaged in the research and development of pharmaceutical drugs and medical devices and their commercial exploitation. Co. focuses on developing products primarily for the consumer healthcare market. Co.'s focus is on sexual healthcare and pain relief. DermaSys® is Co.'s transdermal technology platform, for the absorption of active molecules through the skin. DermaSys® includes MED2002, a topical gel for the treatment of erectile dysfunction; TPR100, a topical diclofenac pain relief gel; TIB200, a topical ibuprofen pain relief gel; and SPR300, a topical methyl salicylate pain relief gel.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.